Omalizumab is approved for patients aged 6 years or older with persistent moderate-to-severe asthma, a positive skin/serum test for at least one perennial allergen, and total serum IgE levels between 30 and 1500 UI/mL Omalizumab is also approved for severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and for chronic spontaneous urticaria (CSU) in patients aged 12 years or older, as stated in Table 2. This evidence concerns the gene IGHE and asthma.